According to Zacks, “CHUGAI PHARMACEUTICAL CO. LTD. is mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products for treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. CHUGAI PHARMACEUTICAL CO. LTD. is based in Tokyo, Japan. “
Separately, The Goldman Sachs Group upgraded Chugai Pharmaceutical from a neutral rating to a buy rating in a report on Thursday, January 13th.
Chugai Pharmaceutical Company Profile (Get Rating)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng.
- Get a free copy of the StockNews.com research report on Chugai Pharmaceutical (CHGCY)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.